Zelira Therapeutics (AU:ZLD)
ASX:ZLD
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$5.95M
Enterprise ValueAU$8.08M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D + Commercialisation ModelVertical capability across R&D, clinical evaluation and regulated commercialisation creates durable optionality: successes can convert into recurring product sales without relying solely on licensing. This integrated model supports multiple value paths (product sales, trials, partnerships) over the next 2–6+ months.
Therapeutic Focus With Structural DemandConcentration on chronic pain leverages a large, persistent addressable market and broader acceptance of cannabinoid solutions. Structural demand for non-opioid pain treatments and expanding clinical research underpin longer-term revenue potential if clinical programmes advance and regulatory pathways improve.
Free Cash Flow Improvement SignalAlthough absolute cash flows are negative, reported slight FCF growth suggests initial operational stabilization. A trend of improving FCF, if sustained, would reduce financing needs and support commercialization investment, making liquidity dynamics less reliant on near-term capital raises.
Bears Say
Sharp Revenue DeclineA near-total revenue collapse signals loss of core commercial activity or transitions between revenue streams. This materially weakens scale economics, undermines ability to fund R&D and go-to-market, and raises execution risk; recovery will require new product uptake or external funding.
Negative Equity / Capital StrainNegative shareholders' equity reflects accumulated losses and creates structural balance-sheet fragility. It limits borrowing capacity, increases refinancing and covenant risk, and typically forces dilutive capital raises to restore solvency—reducing strategic flexibility over a multi-month horizon.
Sustained Losses & Cash BurnPersistent negative margins and cash flow deficits indicate the business is not self-funding operations or growth. Continued burn pressures runway and makes future R&D/commercial investment contingent on external financing, increasing execution and dilution risk absent margin improvement.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 152 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―